MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Non-Invasive Vagus Nerve Stimulation: A non-pharmacological approach to target gait impairment in Parkinson’s disease?

A. Yarnall, R. Morris, H. Hunter, JP. Taylor, M. Baker, L. Rochester (Newcastle Upon Tyne, United Kingdom)

Meeting: 2019 International Congress

Abstract Number: 2137

Keywords: Acetylcholine, Gait disorders: Treatment, Parkinsonism

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Pharmacological Interventions

Session Time: 1:15pm-2:45pm

Location: Les Muses Terrace, Level 3

Objective: To determine whether single dose non-invasive vagus nerve stimulation (nVNS) enhances gait performance in Parkinson’s (PD).

Background: Loss of cholinergic neurons from nucleus basalis of Meynert (nbM) may be a major contributor to the functional decline in gait and cognition in PD (1). Studies of cholinesterase inhibitors for the management of PD-associated gait disorder are underway, however, drugs are not without side-effects. We have recently shown in healthy controls that nVNS can activate cholinergic neurons in the nbM.

Method: This was a single dose double-blind, sham/placebo-controlled study of 30 patients with Parkinson’s, who were equally randomised into sham vs. active nVNS groups. Gait was measured using an instrumented walkway and sensors, with preliminary analysis focussing on step time and step length variability, as predictors of early dopa-resistant gait impairment (2). Attentional fluctuation was measured with computerised cognitive testing.

Results: 29 patients (mean age 63.4 years; disease duration 4.8 years, MDS UPDRS III 27.1) completed the study, with no significant differences for baseline clinical demographics between active (n=14) and sham (n=15) groups. There was an overall decrease in step time and step length variability in the active nVNS group, with the latter statistically significant compared with sham nVNS (% improvement +6.0 vs. -25.4%, p=0.045). No difference in cognitive testing was noted.

Conclusion: This small pilot study has shown that nVNS can improve gait parameters associated with dopa-resistant gait impairment in early PD. Non-invasive VNS therefore has the potential to provide a safe, low-cost therapy that can be delivered in the community. (Also presented at the Parkinson’s UK Research Conference, York, UK, 12th November 2018)

References: (1) Yarnall AJ, Rochester L, Burn DJ. Mov Dis 2011; 26: 2496-503. (2) Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan G, Mollenhauer B, Burn DJ. Neur 2017; 88: 1501-11.

To cite this abstract in AMA style:

A. Yarnall, R. Morris, H. Hunter, JP. Taylor, M. Baker, L. Rochester. Non-Invasive Vagus Nerve Stimulation: A non-pharmacological approach to target gait impairment in Parkinson’s disease? [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/non-invasive-vagus-nerve-stimulation-a-non-pharmacological-approach-to-target-gait-impairment-in-parkinsons-disease/. Accessed May 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/non-invasive-vagus-nerve-stimulation-a-non-pharmacological-approach-to-target-gait-impairment-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley